Global e·dentity™ signs a joint venture to end the spread of Covid in China

Wilmington, DE –December 12, 2022, the Global e-dentity group underlines its humanitarian commitment to saving lives and helping to stop the spread of Covid in China through its patented biometric technology. As of 08 December 2022, a joint venture between the Global e-dentity group & Covid Biometrics China, (GCBC) will operate until 2038.

"Today marks an important step not just with China but with the world, as countries seek to ensure public health protections while facilitating economic growth in the Covid era. The Chinese government over the last 8 months has worked with our engineering teams to design the hardware that will utilize our intellectual property and will soon start using Covid screening devices. The joint venture lays the foundation for sustainable public health success, while simultaneously facilitating growth and prosperity in China and beyond," said Dr. Adams, Chairman of the Board of Management and CEO of Global e-dentity.

Global e-dentity, led by senior vice president Dr. Elvis Tan and CEO Dr. Robert Adams, toured key production plants and R&D centers in China and had a series of meetings focused on core technologies and components to fulfill Covid detection requirements over the last 8 months. They also met with a senior team from the Chinese government's health agency. Global e-dentity's Singapore subsidiary specializing in AI software for Covid Detection was also involved. The two executives tested the handheld scanning devices developed by several Chinese companies around Global e-identity intellectual property that uses chemosensory technique to smell for the detectable odor a body emits when infected by Covid.

According to Dr Adams, "The process is quite simple and works on two principles, one being Chemosensory and the other utilizing light along with a 3D Ultrasound imaging sensor. This can identify in seconds those who are actively infected with Covid."

"Chinese scientists have been able to reduce the light transducer, the 3D ultrasound, and organic chemosensory sensors down to a size of about 3mm & 12mm and the scan time has been reduced from 8 seconds to only 3 seconds. With further US and China joint technology efforts, we expect to reduce the chemosensory sensor down to 1mm or less and by 2024 be ready for use in IoT devices, smartwatches, and smart rings. We are confident that technology will soon permit

chemosensory (smell) sensors that detect diseases like Covid to be built into an application downloaded to mobile phones. China will now start to deploy scanners as one new element of an effort to manage Covid, enhancing their ability to promote public health and ensure economic growth."

Dr. Adams, Chairman, and CEO of Global e-dentity further commented, "We are witnessing a remarkable development, moving in less than a year from a prototype to the first fully functional chemosensory scanners. As health and identity biometrics merge, countries around the world have a new way of achieving critical humanitarian goals during times of complex spread of communicable diseases – keeping people safe while allowing necessary work and private activities to continue."

Global e·dentity™ Inc. is registered as a corporation in Delaware and a leading provider of multi-factor biometrics, digital identity solutions, and now health biometrics. For more information, visit www.globaledentity.com. Global e·dentity™ and product(s) are either registered trademarks or trademarks of Global e·dentity™ Inc in the United States and/or other countries. For more information, press only: Sophia Miller: somiller@globaledentity.com